Austria Approves Reimbursement for Amarin’s VAZKEPA® to Reduce Cardiovascular Risk

Amarin Corporation has secured national reimbursement for VAZKEPA® in Austria, allowing statin-treated adults with elevated triglycerides and established cardiovascular disease to access the treatment starting April 1, 2025. This decision places VAZKEPA® in Austria’s Code of Reimbursement (EKO), offering a new option to reduce cardiovascular risk. With heart disease accounting for 35% of deaths in Austria in 2023 and related hospitalizations exceeding 100,000, the approval underscores the urgent need for innovative cardiovascular treatments.

Aaron Berg, Amarin’s President & CEO, highlighted Austria as the 10th European country to approve VAZKEPA®, following Italy’s decision last year. He praised the company's European team for their efforts in expanding access to the treatment and emphasized VAZKEPA®'s strong scientific backing from the REDUCE-IT study. With recent patent protection extending exclusivity to 2039, Amarin aims to further expand its reach across Europe and globally.